NDAORALCAPSULEPriority Review
Approved
Feb 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
CELONTIN (methsuximide) by Pfizer is clinical pharmacology methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. First approved in 1957.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CELONTIN (methsuximide) is an oral anti-epileptic agent approved in 1957 that suppresses the characteristic spike-and-wave activity associated with absence seizures by depressing motor cortex activity and elevating seizure threshold. It is administered as a capsule and works by reducing the frequency of epileptiform attacks in patients with petit mal seizures.
$0.7MPart D
LOE ApproachingDeclining
As a legacy anti-epileptic approaching loss of exclusivity with minimal Part D spending and modest claim volume, this product operates a small, maintenance-focused team with limited growth opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and…
Pharmacologic Class:
Anti-epileptic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CELONTIN offers limited career growth due to its mature, low-volume lifecycle stage and approaching loss of exclusivity. Roles focus on legacy management, compliance, and customer support rather than innovation, expansion, or leadership development.
Brand Manager
Worked on CELONTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.